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ABSTRACT
Objectives: We undertake a systematic review to examine the
methods used by researchers in developing cost-of-illness
(COI) studies. This review aims to categorize the approaches
that the published literature uses in terms of perspective,
scope, components of care analyzed in the literature, data
sets, and valuation approaches used for direct cost. It draws
conclusions regarding the adequacy of current COI research
methods and makes recommendations on improving them.
Methods: The online bibliographic information service
HealthSTAR (which incorporates MEDLINE) was used to
search for COI studies in the research literature published
during the period from 2000 to 2004. The search strategy
used the term “cost of illness” as a MeSH (medical subject
heading) term.
Results: The HealthSTAR literature search identiﬁed refer-
ences to 650 articles. Review of abstracts resulted in the
identiﬁcation of 170 of these for a more detailed review. This
process identiﬁed 52 articles that met all criteria of COI
studies. We identiﬁed 218 components of care analyzed
across the 52 articles. Private-insurance or employer-claims
data sets comprised the largest source of utilization and cost
information among the studies.
Conclusion: Analyzing cost of illness presents useful oppor-
tunities for communicating with the public and policymakers
on the relative importance of speciﬁc diseases and injuries.
Our research, however, indicates that COI studies employ
varied approaches and many articles have methodological
limitations. Without well-accepted standards to guide
researchers in their execution of these studies, policymakers
and the general public must be wary of the methods used in
their calculation and subsequent results.
Keywords: cost-of-illness, direct cost, standards, systematic
review.
Introduction
Increasingly, researchers and policymakers have turned
to cost-of-illness (COI) research to better describe
health-care spending and populate cost-effectiveness
models. This research promises to equip policymakers
and health-care practitioners with information on the
relative importance of speciﬁc illnesses and injuries in
terms of utilization of all relevant components of
health care and the cost involved.
The popular press is provided with information on
the costs of a variety of illnesses often as a way for
researchers to communicate with the public and poli-
cymakers on the relative impact of diseases at a popu-
lation level. These cost ﬁgures often make their way
into the public policy discussion as state and federal
agencies attempt to fashion intervention programs
aimed at reducing costs, improving health, or both.
For example, the National Center for Chronic Disease
Prevention and Health Promotion issues press releases
on its Web site (http://www.cdc.gov/nccdphp/press) [1]
which directly or indirectly reference cost of illness,
such as:
• stimates of the costs of obesity to the population
in the year 2000 were more than $117 billion.
• The direct care expenditures for osteoporosis frac-
tures range from $12.2 billion to $17.9 billion
each year.
• Cigarette smoking and exposure to tobacco smoke
resulted in $92 billion in productivity losses
annually.
• During 1996, direct medical costs for persons with
disability were $260 billion.
These examples support the point that COI studies
have become increasingly important in both the sub-
stance and the rhetoric of developing interventions in
battling illness and injury in the United States.
Hodgson and Meiners’s [2] seminal review in 1982
provided an analysis of the more than 200 COI studies
that had been published up to that time. They gave
credit to Malzberg (1950) [3] for publishing the ﬁrst
COI study. They also recognized Dorothy Rice, former
head of the National Center for Health Statistics, for
formalizing the methodology distinguishing direct
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costs from indirect costs as used in COI studies.
Figure 1 recaps the growing appearance of these
studies in the research literature since 1990. With the
growing popularity of COI studies, we found it sur-
prising that there is little published guidance to
support the choice of methodological approaches.
Thus, we undertook a systematic review to examine
the methods used by researchers in developing COI
studies. More speciﬁcally, this review aims to catego-
rize the approaches that the published literature uses
in terms of perspective, scope, components of care
analyzed in the literature, data sets, and valuation
approaches used.
Methods
The online bibliographic information service Health-
STAR (which incorporates MEDLINE) was used to
search for COI studies in the research literature pub-
lished during the period from 2000 to 2004. Because
the term “cost of illness” was a medical subject
heading (MeSH) term during the period from 2002 to
2004, it was used as the sole search strategy. Other
search terms were investigated, including “health
expenditures,” “costs,” “cost analysis,” and “eco-
nomic value of life,” but they yielded an overwhelming
number of articles that were unrelated to cost of
illness. Also, the purpose of this systematic review was
to identify the most commonly used methodological
approaches for COI studies, and the articles identiﬁed
using “cost of illness” as a MeSH term provided a
large and representative sample of such articles which
was adequate for this purpose. Because the purpose of
the study was to categorize methodologies and data-
bases used in COI studies in the United States, review
articles were excluded, as were studies using data sets
from outside the United States and non-English-
language articles.
The list of full references, and abstracts when avail-
able, were stored electronically. Two reviewers read
the abstracts to determine whether each article
appeared, in fact, to include a COI analysis. In study-
ing COI research, our focus was to identify and
analyze studies that met certain criteria. Hodgson and
Meiners’s [2] earlier work on COI studies was biased
in favor of analyses that attempted to be more inclu-
sive of all direct and indirect medical costs associated
with an illness. We adopted this bias with a pragmatic
deﬁnition. We deﬁned a COI study as one that includes
cost estimates for at least two components of direct
medical costs. Direct medical costs are deﬁned as pay-
ments made for medical care provided [2]. Studies
including just one component of direct medical cost
were deemed too narrow to meet the intent of COI
studies. Because of the complexity of the methodologi-
cal approaches, this systematic review was limited to
studies of direct cost. A similar review of methodolo-
gies for indirect costs could be the subject of a separate
analysis. In addition, a number of articles were prima-
rily cost-effectiveness analyses, which on examination
relied on cost estimates from the literature rather than
on original COI analyses, and thus were excluded.
When both reviewers agreed from reading the abstract
that the article appeared to include a COI analysis of
direct cost in the United States, the full article was
obtained for further examination. Where abstracts
were unclear, we were liberal in including these articles
in the more detailed review. Articles missing abstracts
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in the HealthSTAR search were eliminated from
further consideration.
Once the full articles were available, the two
reviewers examined the methodology, using a data col-
lection tool to code speciﬁc information. Each reviewer
coded the articles on two levels. The ﬁrst level of data
collected was at the article level. At this level, the
primary screening questions conﬁrmed the prior inclu-
sion criteria: that the article reported original analyses,
that the data sets were US-based, that the article
included direct medical costs, that the article used an
adequate population base, and that the article included
data from more than one component of care with a
breakdown of costs for more than one component. If
the article met these criteria, then additional article-
level information was collected including the perspec-
tive for the analysis (e.g., society, employer, and
insurer) and whether the analyses calculated cost of
illness using an incidence- or prevalence-based
approach.
For articles that met the criteria of the ﬁrst level of
review, a second level of review collected information
on the speciﬁc components of care analyzed in each
article. Thirteen components of care were identiﬁed
and coded, including inpatient hospitalization, emer-
gency department, ambulatory surgery or procedure,
outpatient visit, laboratory or test procedure, other
therapies, nursing home, hospice, home care, medical
devices, prescription medication, over-the-counter
medication, and other. For each component of care,
the sources of the utilization and cost data used in the
calculations of cost of illness were identiﬁed.
Both reviewers coded independently. Disagreements
between reviewers were resolved by consensus after the
article was examined further and discussed by both.
Results
The HealthSTAR literature search identiﬁed references
to 650 articles. The abstract review, described previ-
ously, resulted in the identiﬁcation of 170 of these for
the more detailed review. Although the abstracts for
the 170 identiﬁed COI articles were examined by two
reviewers and abstracts that did not meet criteria were
excluded, there were a substantial number of articles
excluded in the subsequent in-depth review step. The
reasons for eliminating articles from further consider-
ation were clustered into 10 categories. The most fre-
quent reason for elimination was that articles focused
on a single component of care in their analyses (55
articles). Other reasons for exclusion were that the
article only reported estimates from the literature and
did not include original analysis (26 articles), that the
article reported total costs but did not report any
details on how the costs were identiﬁed (16 articles),
that it included a cost-effectiveness analysis without a
COI component (9 articles), that it only included indi-
rect costs (9 articles), or that the article was a review
only (6 articles). An additional reason for excluding
articles was that the results did not reﬂect the cost of
usual care, for example, the article included a nonrep-
resentative sample (9 articles), analyzed an interven-
tion (7 articles), or was a study that compared two
drugs (7 articles). Some articles were excluded for mul-
tiple reasons. This process identiﬁed 52 articles (con-
tained in Table 1) that met all criteria of COI studies
and were subjected to additional analyses.
Perspective
We identiﬁed the perspectives of the 52 articles on
direct cost. Among the perspectives identiﬁed were
societal, health-care system, provider, Medicare/
Medicaid, insurance, employer, and caregiver/patient.
Because many articles did not speciﬁcally identify the
perspective of costs represented, we deduced perspec-
tive from the types of utilization and direct cost data
used in the analysis. Occasionally, researchers would
use more limited data sources, but identify an attempt
to use limited cost calculations in an effort to estimate
a broader set of costs. Nearly half of the 52 articles
(24) represent the capturing of direct costs from the
perspective of society. A third (19 articles) represents
the perspective of either employer or insurance-based
health care. The perspective was Medicare or Medic-
aid for four articles, the caregiver/patient for three
articles, and multiple perspectives for two articles. No
articles reﬂected costs from the perspective of the
health-care system or providers.
Incidence or Prevalence
Of the 52 articles reviewed, 44 (85%) used a preva-
lence approach, 6 (12%) used an incidence approach,
and 2 (3%) used both. COI studies using an incidence
approach employ methodologies that differ con-
siderably from studies using a prevalence approach.
Prevalence-based articles used a variety of cross-
sectional data, while incidence-based articles most
commonly used employer or insurer claims data that
are linkable, permitting new cases of a disease or an
injury to be identiﬁed and followed over the course of
illness or multiple years.
Cost Component
Although our primary emphasis for this systematic
review is on methods used to analyze direct medical
costs, we found that 27 of the 52 articles meeting our
study criteria for direct cost also contained indirect
cost. It is clear that many studies that report direct cost
also include indirect cost and thus examine a broader
spectrum of disease burden. Recommendations regard-
ing methods for indirect costs in COI analyses are
beyond the scope of this article but should be
addressed elsewhere.
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Table 1 References for studies in 2000–2004 that met criteria for cost-of-illness studies
Author Citation
Cost
component Perspective
Incidence/
prevalence N
Count of
components of care
Barnett,A., Birnbaum, H.,
Cremieux, P.Y., Fendrick,A.M.,
Slavin, M. (2000)
Am J Manag Care 6(11):1243–51 1 5 i 3
Birnbaum, H., Morley, M., Leong, S.,
Greenberg, P., Colice, G. (2003)
Pharmaco-economics 21(10):
749–59
1 5 p 14315 4
Birnbaum, H.G., Barton, M.,
Greenberg, P.E., Sisitsky,T.,
Auerbach, R.,Wanke, L.A.,
Buatti, M.C. (2000)
J Occup Environ Med 42(6):
588–96
1 5 p 1580 2
Birnbaum, H.G., Berger,W.E.,
Greenberg, P.E., Holland, M.,
Auerbach, R.,Atkins, K.M., et al.
(2002)
J Allergy Clin Immunol 109(2):
264–70
1 5 p 9602 2
Birnbaum, H.G., Morley, M.,
Greenberg, P.E., Cifaldi, J., Colice,
G.L. (2001)
Arch Int Med 161(22):2725–31 1 5 i 4036 4
Burd, L., Klug, M.G., Coumbe, M.J.,
Kerbeshian, J. (2003)
J Child Neurol 18(8):555–61 2 5 p 3872 2
Calhoun, E.A., McNaughton
Collins, M., Pontari, M.A.,
O’Leary, M., Leiby, B.W., Landis,
R.J. (2004)
Arch Intern Med 164(11):1231–6 1 1 p 167 7
Centers for Disease Control and
Prevention (2003)
MMWR 52(46):1124–7 2 1 p 22435 4
Crown,W.H., Olufade,A., Smith,
J.W., Nathan, R. (2003)
Value Health 6(4):448–56 2 5 p 80534 2
Crystal, S., Johnson, R.W., Harman,
J., Sambamoorthi, U., Kumar, R.
(2000)
J Gerontol B Psychol Sci Soc Sci
55(1):S51–62
2 7 p 7886 5
de Lissovoy G., Zodet, M., Coyne,
K., O’Connell, J.B. (2002)
Manag Care Interface 15(5):46–52 2 5 p 899 3
Ellis, C.N., Drake, L.A.,
Prendergast, M.M.,Abramovits,
W., Boguniewicz, M., Daniel,
C.R., et al. (2002)
J Am Acad Dermatol 46(3):361–70 2 6 p 35404 5
Fendrick,A.M., Monto,A.S.,
Nightengale, B., Sarnes, M.
(2003)
Arch Intern Med 163(4):487–94 1 1 p 4051 3
Garis, R.I., Farmer, K.C. (2002) Manag Care 11(8):43–50 2 4 p 41159 4
Goetzel, R.Z., Long, S.R.,
Ozminkowski, R.J., Hawkins, K.,
Wang, S., Lynch,W. (2004)
J Occup Environ Med 46(4):
398–412
1 5 p 4
Halpern, M., Rentz,A., Murray, M.
(2000)
Neuro- epidemiology 19(2):87–90 2 1 b 128 5
Halpern, M.T., Stanford, R.H.,
Borker, R. (2003)
Respir Med 97 Suppl C:S81–9 1 1 p 447 6
Halpern, M.T., Schmier, J.D.,
Richner, R., Guo, C.,Togias,A.
(2004)
J Asthma 41(1):117–26 2 5 p 27398 3
Hodgson,T.A., Cai, L. (2001) Med Care 39(6):599–615 2 1 p 8
Hu,T.W.,Wagner,T.H., Bentkover,
J.D., Leblanc, K., Zhou, S.Z.,
Hunt,T. (2004)
Urology 63(3):461–5 1 1 p 4
Javitz, H.S.,Ward, M.M., Farber, E.,
Nail, L.,Vallow, S.G. (2002)
J Am Acad Dermatol 46(6):850–60 2 1 p 4
Javitz, H.S.,Ward, M.M.,Watson,
J.B., Jaana, M. (2004)
Am J Manag Care 10:S358–69 2 1 p 7
Kinchen, K.S., Long, S., Orsini, L.,
Crown,W., Swindle, R. (2003)
Int Urogynecol J 14(6):403–11 2 5 p 6672 4
Leong, S.A., Barghout,V., Birnbaum
H.G.,Thibeault, C.E.,
Ben-Hamadi, R., Frech, F., Ofman,
J.J. (2003)
Arch Intern Med 163(8):929–35 1 5 p 1509 4
Levy, R.L.,Von Korff, M.,
Whitehead,W.E., Stang, P.,
Saunders, K., Jhingran P., et al.
(2001)
Am J Gastroenterol 96(11):
3122–9
2 5 p 3153 6
Marciniak, M., Lage, M.J.,
Landbloom, R.P., Dunayevich, E.,
Bowman, L. (2004)
Depress Anxiety 19(2):112–20 1 5 p 1917 5
Mark,T.L.,Woody, G.E., Juday,T.,
Kleber, H.D. (2001)
Drug Alcohol Depend 61(2):
195–206
2 1 p 4
Martin, B.C., Ricci, J.F., Kotzan, J.A.,
Lang, K, Menzin J. (2000)
Alzheimer Dis Assoc Dis 14(3):
151–9
2 4 p 8671 5
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Components of Care
By deﬁnition, this systematic review identiﬁed articles
that analyzed more than one component of care. We
identiﬁed 218 components of care analyzed across the
52 articles, for an average of 4 components per article.
Eight articles contained just 2 components of care, 11
articles contained 3 components of care, and 15
articles contained 4 components of care. The fre-
quency of components covered dropped quickly from
that point, with eight articles covering ﬁve compo-
nents, four articles covering six components, and six
Table 1 continued
Author Citation
Cost
component Perspective
Incidence/
prevalence N
Count of
components of care
Max,W., Rice, D.P., Sung, H.Y.,
Michel, M., Breuer,W., Zhang, X.
(2002)
Cancer 94(11):2906–13 1 1 p 9043 6
Michaud, K., Messer, J., Choi, H.K.,
Wolfe, F. (2003)
Arthritis Rheuma 48(10):2750–62 2 7 p 7527 4
Mohr, P.E., Feldman, J.J., Dunbar, J.L.,
McConkey-Robbins,A., Niparko,
J.K., Rittenhouse, R.K., et al.
(2000)
Int J Technol Assess Health Care
16(4):1120–35
1 1 i 15442 3
Moore, M.J., Zhu, C.W., Clipp, E.C.
(2001)
J Gerontol B Phys Sci Soc Sci
56(4):S219–28
1 7 p 2043 3
Muchmore, L., Lynch,W.D.,
Gardner, H.H.,Williamson,T.,
Burke,T. (2003)
J Occup Environ Med 45(4):
369–78
1 5 p 35714 2
O’Brien, J.A.,Ward,A.J., Patrick,
A.R., Carol, J. (2003)
BMC Health Serv Res 3(1):17 2 5 p 8
Rajbhandary, S.S., Marks, S.M.,
Bock, N.N. (2004)
Int J Tuberc Lung Dis 8(8):1012–6 1 1 p 13 2
Rao, S., Kubisiak, J., Gilden, D.
(2004)
Breast Cancer Res Treat 83(1):
25–32
2 4 i 397 8
Rein, D.B., Kassler,W.J., Irwin, K.L.,
Rabiee, L. (2000)
Obstetr Gynecol 95(3):397–402 2 1 i 3
Rothbard,A.B., Metraux, S., Blank,
M.B. (2003)
Psychiatr Ser 54(9):1240–6 2 4 p 268 3
Sandler, R.S., Everhart, J.E.,
Donowitz, M.,Adams, E., Cronin,
K., Goodman, C., et al. (2002)
Gastroen-terology 122(5):
1500–11
1 1 p 5
Small, G.W., McDonnell, D.D.,
Brooks, R.L., Papadopoulos, G.
(2002)
J Am Geriatr Soc 50(2):321–7 1 1 p 1715 3
Snowden, C.B., Miller,T.R., Jensen,
A.F., Lawrence, B.A. (2003)
Public Health Rep 118(1):10–7 1 1 p 3
Stang, P.E., Crown,W.H., Bizier, R.,
Chatterton, M.L.,White, R.
(2004)
Am J Manag Care 10(5):313–20 1 5 p 73094 4
Strassels, S.A., Smith, D.H., Sullivan,
S.D., Mahajan, P.S. (2001)
Chest 119(2):344–52 1 1 p 238 4
Szucs,T.D., Berger, K., Fisman, D.N.,
Harbarth, S. (2001)
BMC Infect Dis 1(1):5 1 6 b 1565 4
Taylor, D.H., Schenkman, M., Zhou,
J., Sloan, F.A. (2001)
J Gerontol B Phys Sci Soc Sci
56(5):S285–93
1 1 p 4834 3
Weiss, K.B., Sullivan, S.D., Lyttle,
C.S. (2000)
J Allergy Clin Immunol 106(3):
493–9
1 1 p 4
White,T.J. (2001) Am J Manag Health 7(17 Suppl):
S545–50; Discussion S550–2
2 5 p 6477 2
Wilson, L., Brown, J.S., Shin, G.P.,
Luc, K.O., Subak, L.L. (2001)
Obstet Gynecol 98(3):398–406 2 1 p 5
Yelin, E., Cisternas, M.G., Pasta, D.J.,
Trupin, L., Murphy L., Helmick,
C.G. (2004)
Arthritis Rheuma 50(7):2317–26 1 1 p 4457 7
Yelin, E.,Trupin, L., Cisternas, M.,
Eisner, M., Katz, P., Blanc, P.
(2002)
Eur Respir J 19(3):414–21 2 1 p 6
Zimmerman, C.M., Bresee, J.S.,
Parashar, U.D., Riggs,T.L.,
Holman, R.C., Glass, R.I. (2001)
Pediatr Infect Dis J 20(1):14–9 2 5 p 2
Zohrabian,A., Meltzer, M.I., Ratard,
R., Billah, K., Molinari, N.A., Roy,
K. (2004)
Emerg Infect Dis 10(10):1736–44 1 1 i 329 5
Cost component codes: 1 = direct cost only; 2 = direct and indirect cost.
Perspective codes: 1 = societal; 2 = health-care system; 3 = provider; 4 =Medicare/Medicaid; 5 = insurer/employer; 6 =multiple perspectives; 7 = caregiver/patient.
Incidence/prevalence codes: p = prevalence; i = incidence; b = both.
N: N is blank where no speciﬁc sample size was speciﬁed in the study or where multiple sample sizes were included because of the use of multiple databases.
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articles covering seven or more components of care.
The frequency of each component was also deter-
mined. The most frequently analyzed components of
care were outpatient care, including ofﬁce visits (47
articles), hospitalization (44 articles), prescription
medication (41 articles), emergency department
(24 articles), other noncategorized components (21
articles), nursing home (9 articles), home care (12
articles), and laboratory or test procedure (9 articles).
Utilization Data Sources
The current review uncovered a considerable range of
data sets used to identify utilization. These data sets
included both public-use and proprietary data. Private
insurance or employer-claims data sets comprised the
largest source of utilization information among the
studies (21 articles). Single utilization data sets
from the National Center for Health Statistics (e.g.,
National Hospital Discharge Survey [NHDS],
National Ambulatory Medical Care Survey [NAMCS])
were used in 11 articles. Medicaid and Medicare uti-
lization data were used in six articles. Medical Ex-
penditure Panel Survey/National Medical Expenditure
Survey (MEPS)/NMES, which is a national survey with
veriﬁcation from other data sets for multiple compo-
nents of care, was used in six articles. Other national
data sets were used in ﬁve articles. Special surveys were
cited in 10 articles.
Cost Data Sources
Perhaps not surprisingly, cost data sources used were
similar to the utilization data sources. Employer-based
health insurance and claims data were signiﬁcant
sources of cost information for these studies (23
articles). Medicare and Medicaid data also ﬁgured sig-
niﬁcantly as a source of cost-related information (16
articles). MEPS/NMES was used frequently as a single
source of cost data for multiple components of care
(nine articles). Average wholesale price was used in 10
articles to report cost of medication. Other noncatego-
rized cost data sources were cited in nine articles.
Illnesses Analyzed
A wide variety of illnesses are studied in the COI
literature. The most frequent illness studied in the COI
articles that met our inclusion criteria was arthritis (six
articles). Respiratory diseases, urinary diseases, and
Alzheimer’s disease were the subject of three articles
each. Chronic obstructive pulmonary disease, irritable
bowel syndrome, asthma, and allergic rhinitis were
each the subject of two articles in the 5-year period
(2000–2004).
Discussion
COI studies are being relied on increasingly to inform
both public and private decision-makers with regard to
the expenditures made on behalf of individuals for
illnesses and injuries occurring in our population.
These studies help drive decisions about future insur-
ance beneﬁts, research efforts in curbing and control-
ling disease and injury, and development of programs
to improve the health of the population. Unfortu-
nately, one of the ﬁndings of the current review of COI
articles was the limitation in this body of research.
One of the most signiﬁcant limitations reﬂects on
the very deﬁnition of a COI study. Although one goal
of this systematic review was to ﬁnd research articles
that broadly attempted to account for all components
of care in the assessment of the costs for particular
illness, we found that many COI articles only included
one component of care. When these were eliminated,
surprisingly, the remaining articles only averaged four
components of care. This lack of breadth indicates that
most studies are more limited in scope than the COI
methodologies discussed in Hodgson and Meiners [2],
Rice et al. [4], and Rice [5]. Readers of this literature
must be aware that COI analyses of a limited number
of components of care underestimate the full cost of
treating the disease or injury under study. Such analy-
ses will not be replicated by other studies examining
other components of care, leading to disparate esti-
mates of the magnitude of the cost for speciﬁc diseases.
Another troubling ﬁnding is that many studies in
this review lacked clarity with regard to the methods
used in calculating cost of illness. One of the most
frequent omissions was speciﬁcation of what consti-
tuted “cost.” For example, studies relying on insurance
or claims-based data often did not clarify whether
“cost” information represented charges from provid-
ers or actual reimbursed amounts. Charges have been
shown to average more than twice the actual cost of
delivering care [6], making COI calculations suscep-
tible to considerable inﬂuence depending on which
metric of “cost” is used. When the metric remains
unclear or unspeciﬁed, the value of the COI ﬁndings is
seriously diminished.
Despite these limitations, one purpose of this study
was to identify the most commonly used approaches
for conducting COI analyses, as a guide for future
researchers. The current analyses identiﬁed three
popular approaches. The most frequently used data
sources were from insurance or employer claims data.
The second most popular approach used publicly
available data sets from the NCHS or from the Agency
for Healthcare Research and Quality. Two data
sources tied for third place in terms of popularity in
COI studies. These were MEPS/NMES and Medicare/
Medicaid data. Each of these approaches has advan-
tages and disadvantages.
A number of studies relied on MarketScan data
provided by MEDSTAT as a source of utilization infor-
mation. The MarketScan database (The MEDSTAT
Group, Ann Arbor, MI) contains claims information
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from approximately 65 large American corporations
that provide coverage to their employees, dependents,
retirees, and Consolidated Omnibus Reconciliation
Act of 1986 (COBRA) continuees. MarketScan data
are available for sale to researchers. Its large popula-
tion size permits COI analyses of most prevalent dis-
eases. The fact that its database originates largely from
employed individuals and their dependents permits
COI analyses in the population less than 65 years of
age including children. The large number of corpora-
tions contributing data assures geographic and demo-
graphic representation.
Another frequently cited source of utilization
information was private insurance-based claims data,
often from Fortune 100 companies. Articles that used
insurance claims data to identify utilization also used
those data to capture cost. Private insurance-based
claims data are not publicly available, in that the
data must be accessed from the insurer, if it is avail-
able to outside users at all. Some of the articles using
these data were by researchers who were employed
by a particular employer or insurance company.
Additionally, many of the data sources used were
proprietary and, in the cases of speciﬁc employer-
based studies, the original source of the data was not
precisely identiﬁed (the employer was not identiﬁed).
Although these research efforts are meaningful for
private employers, these studies may not be readily
replicable and may not be generalizable for purposes
of public policymaking.
Employer or insurance-based information will carry
with it the biases inherent in the beneﬁts structure of
these programs. Because copays, deductibles, and
breadth of insurance coverage are not uniform from
employer to employer or from plan to plan, generaliz-
ing these ﬁndings over time and to broader popula-
tions may be inappropriate. Furthermore, because
these cost calculations come from the experience of
insured individuals, they cannot directly relate the cost
of illness for the uninsured. Claims-based information
provides the advantage, however, of more precisely
matching value and utilization within a plan. This is a
strength when analyzing cost of illness at the plan
level, where beneﬁts are similar, or within geographic
areas that might have similar cost and beneﬁt struc-
tures for a population of insured persons.
Medicare and Medicaid data also served as signiﬁ-
cant sources of utilization data for these studies. In
addition, Medicare utilization data were often cited as
a secondary source of data, effectively supplementing
other sources of information in analyzing societal-level
impact of particular illnesses. Use of Medicare or Med-
icaid utilization data can be appropriate in cases where
the illness under study occurs predominantly in the
publicly covered population. This could be true for
certain types of health-care conditions that are particu-
larly prevalent in the elderly, for example using Medi-
care data to examine the cost of illness of stroke or
osteoarthritis. Where utilization is different between
populations, however, these public data may be less
reliable in providing complete information about all
types of patients.
More often, Medicaid and Medicare data were used
to inform the cost side of calculations for cost of
illness. Because Medicaid cost data differ from state to
state and within states, researchers and policymakers
must be mindful as to how these cost data are applied
to relevant utilization data and utilization from par-
ticular areas of the country. Additionally, in rural and
underserved areas, critics often charge that Medicare
programs provide low reimbursement to providers,
and so this criticism must be factored into an analysis
of costs that use these data. Certainly, if the perspective
of the analysis reﬂects these public programs, then
using this data would be appropriate. These issues can
be resolved when national Medicare data are used to
assign value to utilization.
A variety of other federal data sources were also
utilized, with advantages and disadvantages to these
data sets related to time frame, scope of utilization,
and inclusion of cost data. A number of these, such as
the Nationwide Inpatient Sample of the Healthcare
Cost and Utilization Project (NIS/HCUP) and several
data sets collected by the NCHS, focus on a single
component of utilization. NCHS data sets include the
NHDS, the NAMCS, the National Hospital Ambula-
tory Medical Care Survey, the National Nursing Home
Survey, and the National Home and Hospice Care
Survey. These data sets are publicly available at a low
cost. Most are available annually. The samples for
these data sets are carefully constructed and can be
weighted to the US population. They cannot, however,
be linked across data sets or across a year, prohibiting
identiﬁcation of episodes of care. Another shortcoming
is that they do not include cost or charge information.
Many researchers overcome this deﬁcit by assigning
national Medicare reimbursement rates to units of uti-
lization. The NIS/HCUP data do include cost informa-
tion, but it is limited to total hospital charges.
Several of these data sources span multiple compo-
nents of care, a decided advantage for use in COI
studies. The National Health and Nutrition Examina-
tion Survey III (NHANES III) contains survey data
across components of care and has been used in several
articles. Earlier NHANES data were collected on a
continuous basis but released in 6-year increments,
complicating 1-year analyses of cost of illness. More
recent data are released in 2-year increments. The
current review found that the MEPS was a popular
source for utilization and cost information. MEPS is a
nationally representative sample of households and
their health services usage and costs—both insurance-
based and out-of-pocket expenses. Efforts are made to
verify utilization and cost data. In earlier years, it was
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only available periodically, but now MEPS data are
collected annually.
A concern with many data sets is the limited
number of cases identiﬁed for the disease or for the
injury under study. As shown in Table 1, the number of
cases was not identiﬁed in some articles or was quite
small in others, raising concerns about the stability of
estimates and generalizability. For relatively rare ill-
nesses or injuries, combining data sets across years
may help alleviate this problem.
Conclusion
Analyzing cost of illness presents useful opportunities
for communicating with the public and policymakers
on the relative importance of speciﬁc diseases and inju-
ries. Over time, these studies have become vitally
important to the development of research and policy
initiatives aimed at more cost-effectively treating and
preventing illness. Our research indicates that, unfor-
tunately, many COI studies have focused exclusively
on a subset of total health-care expenditures, not all
expenditures resulting from a particular disease or
injury. Often, cost data used are proprietary, which
presents difﬁculties in future replication and validation
of this research. Without well-accepted standards to
guide researchers in their execution of these studies,
policymakers and the general public must be wary of
the data sources and methods used in their calculation.
This is particularly important in light of the natural
tendency to compare costs of illness across diseases in
prioritizing the allocation of scarce resources for
research and intervention.
Because these studies will continue to be important
contributions to understanding our investment in
health care, public and private grant-makers and
researchers should work to standardize terminology
and methods of executing these studies. Among
standards that should be established for these studies
are:
• Disclosure of perspectives used in guiding the
study. Understanding the perspective from which
costs are captured is critical to a clear understand-
ing of cost of illness.
• Inclusion, whenever possible, of all affected com-
ponents of care. Analyses limited to only a few
components of care will underestimate the cost of
illness for the conditions under study and limit
generalizability of the ﬁndings.
• Identiﬁcation of the components of care analyzed.
Researchers must clearly articulate those particu-
lar health-care cost segments included in their
analysis. A standard language for components of
care should be created and data elements should
be matched against these to ensure clarity in the
identiﬁcation of cost categories.
• Description of data sources. This will enable
future researchers to replicate and improve on the
analysis of COI studies by understanding what the
data used represent.
• Use, whenever possible, of publicly available data
sets. This will permit other researchers to replicate
the ﬁndings, will enhance generalizability across
all payers, and will facilitate understanding of the
data elements used in the analyses.
• Data sets should be used that permit a reasonable
number of cases to be identiﬁed so that estimates
are stable. Extracting data from multiple years
may be helpful for relatively rare conditions.
• COI studies often project individual costs to the
US population. Weights assigned to cases in
public-use data sets can be used for such projec-
tions. Another approach multiplies prevalence
estimates by average costs to project to national
costs, in which case considerable care must be
given to accurately identifying the prevalence for
the condition.
• Identiﬁcation of costs captured. Costs of care
come in a wide variety of forms, including out-of-
pocket, insurance-based reimbursement, charges,
indirect costs, etc. Studies should clearly articulate
whether the cost data used represent the actual
cost of delivering care, dollars exchanged for the
provision of care, or simply provider charges,
which may be subject to inﬂating (such as for
cardiac surgery) or discounting (such as in pre-
ferred provider arrangements).
• Disclosure of the year reﬂected in the utilization
data and in its valuation. This is important for
interpreting ﬁndings when patterns of treatment
change over time. Also, the year that costs were
valued is important when comparing ﬁndings
across studies using different years, so that inﬂa-
tion factors can be appropriately applied and dis-
counting can be employed.
• Description of the strategy for using primary and
secondary diagnosis data. Where diagnostic data
are used, studies should declare how they have
dealt with the use of primary and secondary
diagnoses in capturing cost information [7]. In
particular, were cases limited to utilization where
the speciﬁc International Classiﬁcation of Dis-
eases, Ninth Revision codes were listed ﬁrst or
was a broader inclusion rule used? In addition,
were all costs for persons with the disease
included, or only those costs for treating the spe-
ciﬁc disease?
As called for by Bloom [8], standards to guide the
methodology of COI studies will aide interpretation of
ﬁndings and comparison of results across studies and
diseases. At the very least, as listed above, researchers
should be mindful of their responsibility to disclose
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pertinent details of their methods to permit others to
understand and replicate their results. With the
increasing popularity of COI studies, the standardiza-
tion of methods becomes more critical to permit poli-
cymakers and the general public to better understand
our investment in health care, and to drive decisions
about future insurance beneﬁts, efforts in curbing and
controlling disease and injury, and development of
programs to improve the health of the population.
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